A Phase 1 clinical trial will test the effectiveness of a new vaccine developed to protect against mosquito-borne diseases. Researchers from the National Institutes of Health (NIH), are testing a new vaccine studied to target mosquito saliva to protect against mosquito-borne diseases.
The National Institute of Allergy and Infectious Diseases or NIAID, which is a part of the NIH has started a Phase 1 clinical trial of a new vaccine that could provide widespread protection against a variety of mosquito-borne diseases like Dengue Fever, Malaria, Zika and West Nile virus. SEEK, a London-based pharmaceutical company created the vaccine, AGS-v, and is designed to trigger an immune response to mosquito saliva instead of a specific virus or parasite.
AGS-v is made up of four synthetic proteins from salivary glands of mosquito and is designed to induce antibodies in a vaccinated person to cause a modified allergic response to prevent infection.
Dr. Anthony S. Fauci, NIAID director said in a press release, “Mosquitoes cause more human disease and death than any other animal.” He further added, “A single vaccine capable of defending against the scourge of mosquito-borne diseases is a novel concept that, if proven successful, would be a monumental public health advance.”
The trial will consist of 60 healthy adults having age between 18 to 50 and will divide participants into three groups. The first group will receive two injections of AGS-v 21 days apart. The second group will receive two injections of AGS-v combined with an adjuvant of an oil and water mixture 21 days apart, and the third group will receive two injections with placebos of sterile water 21 days apart.
After 21 days, the participants will be made public to biting mosquitoes that do not carry parasites or viruses in a controlled environment. The Phase 1 clinical trial is expected to be complete by summer 2018.